Exploring medical cannabis use in individuals with a traumatic brain injury

Q4 Biochemistry, Genetics and Molecular Biology Exploration of medicine Pub Date : 2023-06-30 DOI:10.37349/emed.2023.00150
Elizabeth N. R. Schjelderup, Caroline A. MacCallum, Lindsay A. Lo, Jessie Dhillon, A. Christiansen, Carly Pistawka, Kathryn Rintoul, W. Panenka, A. Barr
{"title":"Exploring medical cannabis use in individuals with a traumatic brain injury","authors":"Elizabeth N. R. Schjelderup, Caroline A. MacCallum, Lindsay A. Lo, Jessie Dhillon, A. Christiansen, Carly Pistawka, Kathryn Rintoul, W. Panenka, A. Barr","doi":"10.37349/emed.2023.00150","DOIUrl":null,"url":null,"abstract":"Aim: Traumatic brain injury (TBI) is a common neurological condition, which can present with a wide range of neuropsychological symptoms. Treating this broad spectrum of symptoms represents a significant medical challenge. In part because of this, there is growing interest in the use of medical cannabis to treat the sequelae of TBI, as medical cannabis has been used to treat multiple associated conditions, such as pain. However, medical cannabis represents a heterogeneous collection of therapies, and relatively little is known about their effectiveness in treating TBI symptoms. The aim of the present study was therefore to assess medical cannabis use in patients with TBI.\nMethods: In the present study, a retrospective chart review was conducted of patterns of cannabis use and TBI symptoms in individuals who used medical cannabis to treat TBI-related symptoms. All subjects were recruited from a medical cannabis clinic, where cannabis was authorized by physicians, using licensed cannabis products. A total of 53 subjects provided written consent to have their charts reviewed.\nResults: Neuropsychiatric conditions, including depression, pain, and anxiety were frequent in this group. The most common forms of medical cannabis consumption at intake included smoking, vaping, and oral ingestion. Patients used a combination of high tetrahydrocannabinol (THC)/low cannabidiol (CBD) and low THC/high CBD products, typically 1–3 times per day. Medical cannabis appeared to be relatively well-tolerated in subjects, with few serious side effects. At follow-up, subjects self-reported improvements in TBI symptoms, although these were not statistically significant when assessed using validated questionnaires.\nConclusions: Overall findings indicate modest potential benefits of medical cannabis for TBI, but further research will be required to validate these results.","PeriodicalId":72999,"journal":{"name":"Exploration of medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Exploration of medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37349/emed.2023.00150","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
引用次数: 0

Abstract

Aim: Traumatic brain injury (TBI) is a common neurological condition, which can present with a wide range of neuropsychological symptoms. Treating this broad spectrum of symptoms represents a significant medical challenge. In part because of this, there is growing interest in the use of medical cannabis to treat the sequelae of TBI, as medical cannabis has been used to treat multiple associated conditions, such as pain. However, medical cannabis represents a heterogeneous collection of therapies, and relatively little is known about their effectiveness in treating TBI symptoms. The aim of the present study was therefore to assess medical cannabis use in patients with TBI. Methods: In the present study, a retrospective chart review was conducted of patterns of cannabis use and TBI symptoms in individuals who used medical cannabis to treat TBI-related symptoms. All subjects were recruited from a medical cannabis clinic, where cannabis was authorized by physicians, using licensed cannabis products. A total of 53 subjects provided written consent to have their charts reviewed. Results: Neuropsychiatric conditions, including depression, pain, and anxiety were frequent in this group. The most common forms of medical cannabis consumption at intake included smoking, vaping, and oral ingestion. Patients used a combination of high tetrahydrocannabinol (THC)/low cannabidiol (CBD) and low THC/high CBD products, typically 1–3 times per day. Medical cannabis appeared to be relatively well-tolerated in subjects, with few serious side effects. At follow-up, subjects self-reported improvements in TBI symptoms, although these were not statistically significant when assessed using validated questionnaires. Conclusions: Overall findings indicate modest potential benefits of medical cannabis for TBI, but further research will be required to validate these results.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
探索创伤性脑损伤患者使用医用大麻的情况
目的:创伤性脑损伤(TBI)是一种常见的神经系统疾病,可表现出广泛的神经心理症状。治疗这种广泛的症状是一项重大的医学挑战。部分原因是,人们对使用医用大麻治疗创伤性脑损伤后遗症越来越感兴趣,因为医用大麻已被用于治疗多种相关疾病,如疼痛。然而,医用大麻代表了一系列不同的疗法,人们对其治疗创伤性脑损伤症状的有效性知之甚少。因此,本研究的目的是评估TBI患者使用医用大麻的情况。方法:在本研究中,对使用医用大麻治疗TBI相关症状的个体的大麻使用模式和TBI症状进行了回顾性图表审查。所有受试者都是从一家医用大麻诊所招募的,该诊所的大麻由医生授权,使用许可的大麻产品。共有53名受试者提供了书面同意书,同意对其图表进行审查。结果:该组患者经常出现神经精神疾病,包括抑郁、疼痛和焦虑。摄入时最常见的医用大麻消费形式包括吸烟、吸电子烟和口服。患者使用高四氢大麻酚(THC)/低大麻二酚(CBD)和低THC/高CBD产品的组合,通常每天1-3次。医用大麻在受试者中的耐受性似乎相对较好,几乎没有严重副作用。在随访中,受试者自我报告TBI症状的改善,尽管使用经验证的问卷进行评估时,这些症状在统计学上并不显著。结论:总体研究结果表明,医用大麻对创伤性脑损伤的潜在益处不大,但还需要进一步的研究来验证这些结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
2.10
自引率
0.00%
发文量
0
审稿时长
13 weeks
期刊最新文献
The future of cervical cancer prevention: advances in research and technology Impact of vitamin D on ultraviolet-induced photoaging and skin diseases Physiologically driven nanodrug delivery system for targeted lung cancer treatment Effects of alimentary-derived bacterial metabolites on energy metabolism in colonic epithelial cells and inflammatory bowel diseases Medicinal and immunological aspects of bacteriophage therapy to combat antibiotic resistance
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1